A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

NCT00000633 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: gp160 Vaccine (Immuno-AG)
BIOLOGICAL: Hepatitis B Vaccine (Recombinant)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]